C4 Therapeutics, Inc. (CCCC)
| Market Cap | 342.01M +127.7% |
| Revenue (ttm) | 35.04M +2.3% |
| Net Income | -101.42M |
| EPS | -0.91 |
| Shares Out | 123.03M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,275,294 |
| Open | 2.640 |
| Previous Close | 2.610 |
| Day's Range | 2.600 - 2.846 |
| 52-Week Range | 1.690 - 5.170 |
| Beta | 3.08 |
| Analysts | Strong Buy |
| Price Target | 12.86 (+362.59%) |
| Est. Earnings | Nov 5, 2026 |
About CCCC
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable monodac targeting IKZF1 and IKZF3, or IKZF1/3 to address a need across multiple lines of therapy in multiple myeloma, which has competed its phase 1. The company is also developing oncology product candidate, CFT8919, an orally bioavailable, allosteric, mutant-selective bidac degrader of epidermal growth factor receptor, with an L858R mutat... [Read more]
Financial Performance
In 2025, C4 Therapeutics's revenue was $35.95 million, an increase of 1.02% compared to the previous year's $35.58 million. Losses were -$104.99 million, -0.31% less than in 2024.
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for CCCC stock is "Strong Buy." The 12-month stock price target is $12.86, which is an increase of 362.59% from the latest price.
News
C4 Therapeutics initiated with an Overweight at JPMorgan
JPMorgan initiated coverage of C4 Therapeutics (CCCC) with an Overweight rating and $10 price target The firm cites the potential of the company’s lead asset cemsidomide in multiple myeloma for…
C4 Therapeutics Slides: Corporate presentation
C4 Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on September 25, 2026.
C4 Therapeutics presents biomarker data from Phase 1 trial of cemsidomide
C4 Therapeutics (CCCC) presented new biomarker data from its Phase 1 clinical trial of cemsidomide in combination with dexamethasone in patients with relapsed/refractory multiple myeloma, RRMM, in a p...
C4 Therapeutics Presents New Biomarker Data from the Cemsidomide Phase 1 Trial with Dexamethasone and Phase 1b Trial with Elranatamab (ELREXFIO®) in Relapsed/Refractory Multiple Myeloma at the 23rd International Myeloma Society (IMS) Annual Meeting
Immunomodulatory Effects of Cemsidomide with Dexamethasone from Phase 1 Trial Demonstrated Robust T-cell Activation, a Key Component of Cemsidomide's Dual Mechanism of Action
C4 Therapeutics Transcript: Wells Fargo 21st Annual Healthcare Conference
Cemsidomide is advancing in multiple myeloma with strong efficacy, tolerability, and ongoing pivotal trials, including combination studies with T-cell engagers. The late-line market is expected to grow, and the platform is expanding into new disease areas, supported by collaborations and a runway through 2028.
C4 Therapeutics to Present New Biomarker Data on the Immunomodulatory Effects of Cemsidomide in Combination with Dexamethasone from its Phase 1 Relapsed/Refractory Multiple Myeloma Trial at the 23rd International Myeloma Society (IMS) Annual Meeting
WATERTOWN, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation (TPD) sc...
C4 Therapeutics reports Q2 EPS (18c), consensus (23c)
Reports Q2 revenue $6.64M, consensus $4M. “The first half of 2026 was a period of execution for cemsidomide, our next-generation IKZF1/3 degrader, and our clinical development plan. At the EHA…
C4 Therapeutics Earnings release: Q2 2026
C4 Therapeutics released its Q2 2026 earnings on August 11, 2026, summarizing the period's financial results.
C4 Therapeutics Quarterly report: Q2 2026
C4 Therapeutics has published its Q2 2026 quarterly earnings report on August 11, 2026.
C4 Therapeutics Slides: Corporate presentation
C4 Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on August 10, 2026.
C4 Therapeutics Transcript: AGM 2026
The meeting confirmed a quorum and addressed four proposals, including director elections, executive compensation, auditor ratification, and a stock plan amendment. All proposals passed by majority vote, and no shareholder questions were raised.
C4 Therapeutics Transcript: KOL event
The event highlighted the evolving multiple myeloma landscape and the foundational role of IKZF1/3 degraders, with cemsidomide showing strong efficacy and safety in heavily pre-treated patients. Strategic development includes late-line and combination trials, aiming to establish cemsidomide as a backbone therapy.
C4 Therapeutics Slides: KOL event
C4 Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on June 18, 2026.
C4 Therapeutics presents further analysis from cemsidomide trial
C4 Therapeutics (CCCC) will present further analysis from its fully enrolled Phase 1 trial of cemsidomide, a next-generation oral IKZF1/3 degrader, in combination with dexamethasone for the treatment ...
C4 Therapeutics Presents Phase 1 Data at European Hematology Association (EHA) 2026 Congress Highlighting Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader for Multiple Myeloma in Heavily Pretreated Relapsed/Refractory Population
At the 100 µg Recommended Phase 2 Dose (RP2D), Cemsidomide Demonstrated a 53% Overall Response Rate, Including Complete Responses and Minimal Residual Disease (MRD) Negative Status
C4 Therapeutics Slides: Corporate presentation
C4 Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on June 11, 2026.
C4 Therapeutics Transcript: Jefferies Global Healthcare Conference 2026
Cemsidomide demonstrates strong efficacy and a differentiated safety profile in late-line multiple myeloma, with pivotal studies underway and a market opportunity up to $4 billion. Strategic focus is on combination regimens and innovative partnerships, including DACs with Roche, while the preclinical pipeline and market positioning remain underappreciated.
C4 Therapeutics jumps after Bristol Myers myeloma data
Shares of C4 Therapeutics (CCCC) are up 19%, or 70c, to $4.36 in midday trading after Bristol Myers (BMY) announced positive Phase 3 multiple myeloma data.
C4 Therapeutics Transcript: 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA
Cemsidomide's phase II data show strong efficacy and safety in late-line settings, with ongoing global enrollment and combination studies progressing as planned. The strategy emphasizes differentiation from competitors by focusing on late-line and BiTE combinations, with pivotal data expected in 2027.
C4 Therapeutics to Participate in Upcoming Conferences
WATERTOWN, Mass., May 20, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation (TPD) scie...
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
WATERTOWN, Mass., May 18, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, t...
C4 Therapeutics reports Q1 EPS (20c), consensus (26c)
Reports Q1 revenue $6.15M, consensus $4.42M. “During the first quarter, we made strong progress advancing cemsidomide as a potential best-in-class IKZF1/3 degrader for the treatment of multiple myelom...
C4 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights
WATERTOWN, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation (TPD) scie...
C4 Therapeutics Quarterly report: Q1 2026
C4 Therapeutics has published its Q1 2026 quarterly earnings report on May 12, 2026.
C4 Therapeutics Earnings release: Q1 2026
C4 Therapeutics released its Q1 2026 earnings on May 12, 2026, summarizing the period's financial results.